{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T02:40:26Z","timestamp":1775616026948,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["102-2320-B-002-005"],"award-info":[{"award-number":["102-2320-B-002-005"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11096-018-0698-5","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T05:55:13Z","timestamp":1532584513000},"page":"911-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone"],"prefix":"10.1007","volume":"40","author":[{"given":"Jun-Hong","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunn-Fang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela W.-F.","family":"On","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-I.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"issue":"5","key":"698_CR1","first-page":"929","volume":"46","author":"HR Manasse Jr","year":"1989","unstructured":"Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm. 1989;46(5):929\u201344.","journal-title":"Am J Hosp Pharm."},{"issue":"6","key":"698_CR2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1056\/NEJM199102073240604","volume":"324","author":"TA Brennan","year":"1991","unstructured":"Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324(6):370\u20136.","journal-title":"N Engl J Med"},{"issue":"18","key":"698_CR3","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/archinte.1995.00430180043006","volume":"155","author":"JA Johnson","year":"1995","unstructured":"Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949\u201356.","journal-title":"Arch Intern Med."},{"issue":"9237","key":"698_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"key":"698_CR5","first-page":"2013","volume-title":"Remington: the science and practice of pharmacy","author":"RK Middleton","year":"2013","unstructured":"Middleton RK. Adverse drug reactions. In: Allen LV, editor. Remington: the science and practice of pharmacy, vol. 2. 21st ed. London: Pharmaceutical Press; 2013. p. 2013\u201322.","edition":"21"},{"key":"698_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/978-3-642-20195-0_17","volume":"205","author":"V Vlahovi\u0107-Pal\u010devski","year":"2011","unstructured":"Vlahovi\u0107-Pal\u010devski V, Mentzer D. Postmarketing surveillance. Handb Exp Pharmacol. 2011;205:339\u201351.","journal-title":"Handb Exp Pharmacol"},{"key":"698_CR7","first-page":"173","volume-title":"Mann\u2019s pharmacovigilance","author":"P Bahri","year":"2014","unstructured":"Bahri P, Arlett P. Regulatory pharmacovigilance in the European Union. In: Andrews EB, Moore N, editors. Mann\u2019s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014. p. 173\u201384.","edition":"3"},{"key":"698_CR8","volume-title":"Mann\u2019s pharmacovigilance","year":"2014","unstructured":"Andrews EB, Moore N, editors. Mann\u2019s pharmacovigilance. 3rd ed. Chichester: Wiley; 2014.","edition":"3"},{"key":"698_CR9","unstructured":"Taiwan National Adverse Drug Reactions Reporting System. http:\/\/adr.fda.gov.tw."},{"issue":"1","key":"698_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1759-8893.2011.00077.x","volume":"3","author":"AW-F On","year":"2012","unstructured":"On AW-F, Chih LH, Liu C, Lin KH, Huang YW, Tai HY, et al. A unique drug-injury relief system in Taiwan: comparing drug-injury compensation in different countries. J Pharm Health Serv Res. 2012;3(1):3\u20139.","journal-title":"J Pharm Health Serv Res"},{"issue":"3","key":"698_CR11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00204-015-1456-2","volume":"89","author":"ES Bj\u00f6rnsson","year":"2015","unstructured":"Bj\u00f6rnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327\u201334.","journal-title":"Arch Toxicol"},{"key":"698_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2015.12.017","volume":"28","author":"A Licata","year":"2016","unstructured":"Licata A. Adverse drug reactions and organ damage: the liver. Eur J Intern Med. 2016;28:9\u201316.","journal-title":"Eur J Intern Med."},{"issue":"12","key":"698_CR13","doi-asserted-by":"publisher","first-page":"2173-89.e8","DOI":"10.1016\/j.cgh.2015.06.017","volume":"13","author":"JH Lewis","year":"2015","unstructured":"Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015;13(12):2173-89.e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"698_CR14","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s40264-014-0182-7","volume":"37","author":"JR Senior","year":"2014","unstructured":"Senior JR. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 2014;37(Suppl 1):S9\u201317.","journal-title":"Drug Saf"},{"issue":"3","key":"698_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","volume":"34","author":"PB Watkins","year":"2011","unstructured":"Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243\u201352.","journal-title":"Drug Saf"},{"issue":"4","key":"698_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple R. Hy\u2019s Law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf. 2006;15(4):241\u20133.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"698_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40264-013-0119-6","volume":"37","author":"X Shen","year":"2014","unstructured":"Shen X, Yuan Z, Mei J, Zhang Z, Guo J, Wu Z, et al. Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy\u2019s Law. Drug Saf. 2014;37(1):43\u201351.","journal-title":"Drug Saf"},{"issue":"1","key":"698_CR18","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hep.26208","volume":"58","author":"M Chen","year":"2013","unstructured":"Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58(1):388\u201396.","journal-title":"Hepatology"},{"key":"698_CR19","unstructured":"Cordarone\u00ae (amiodarone HCl) tablets package insert (Cordarone, revised March 27, 2015). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/018972s047lbl.pdf."},{"key":"698_CR20","unstructured":"US Food and Drug Administration. Medication guide: amiodarone HCl. Washington, DC: US Food and Drug Administration, 2004. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/018972s038s039lbl.pdf."},{"issue":"1","key":"698_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.dld.2005.06.004","volume":"38","author":"E Bj\u00f6rnsson","year":"2006","unstructured":"Bj\u00f6rnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38(1):33\u20138.","journal-title":"Dig Liver Dis."},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/DHPS.S48640","volume":"5","author":"M Nasser","year":"2013","unstructured":"Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCullough PA. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf. 2013;5:191\u20138.","journal-title":"Drug Healthc Patient Saf."},{"key":"698_CR23","first-page":"617943","volume":"2013","author":"N Hussain","year":"2013","unstructured":"Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943.","journal-title":"ISRN Cardiol."},{"issue":"12","key":"698_CR24","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.freeradbiomed.2011.09.004","volume":"51","author":"G Serviddio","year":"2011","unstructured":"Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Capitanio N, Tamborra R, Romano AD, Quinto M, Blonda M, Vendemiale G, Altomare E. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic Biol Med. 2011;51(12):2234\u201342.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"698_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/toxsci\/kfr266","volume":"125","author":"J Lu","year":"2012","unstructured":"Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci. 2012;125(1):126\u201333.","journal-title":"Toxicol Sci"},{"key":"698_CR26","first-page":"10","volume":"53","author":"P-H Chao","year":"2016","unstructured":"Chao P-H, Huang C-Y, Chen W-W. An analysis on 2015 post-marketing spontaneous reports of adverse drug reactions. Drug Saf Newsl. 2016;53:10\u20138 (in Chinese).","journal-title":"Drug Saf Newsl"},{"key":"698_CR27","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA\u00ae). http:\/\/www.meddra.org\/about-meddra\/organisation\/msso."},{"key":"698_CR28","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2013. Oslo, Norway: Institute of Public Health, 2012. http:\/\/www.whocc.no\/filearchive\/publications\/1_2013guidelines.pdf."},{"key":"698_CR29","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on behalf of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 18.0. https:\/\/www.meddra.org\/software-packages, 2015."},{"issue":"1","key":"698_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cld.2016.08.005","volume":"21","author":"CJ Iasella","year":"2017","unstructured":"Iasella CJ, Johnson HJ, Dunn MA. Adverse drug reactions: type A (intrinsic) or type B (idiosyncratic). Clin Liver Dis. 2017;21(1):73\u201387.","journal-title":"Clin Liver Dis"},{"key":"698_CR31","unstructured":"European Commission in consultation with the European Medicines Agency. Volume 9. Pharmacovigilance: medicinal products for human use and veterinary medicinal products. http:\/\/ec.europa.eu\/DocsRoom\/document\/2809\/attachments\/l\/translations\/en\/renditions\/pdf. Accessed 27 June 2018."},{"issue":"7","key":"698_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ajg.2014.131","volume":"109","author":"NP Chalasani","year":"2014","unstructured":"Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950\u201366.","journal-title":"Am J Gastroenterol"},{"key":"698_CR33","unstructured":"Thomson Reuters Healthcare. Micromedex computerized clinical information system. Micromedex website, 2015. micromedex.com. Accessed 5 Aug 2015."},{"key":"698_CR34","unstructured":"Guo T, Gelperin K, Senior J. A tool to help you decide (detect potentially serious liver injury). US Food and Drug Association, 2008. http:\/\/www.fda.gov\/downloads\/Drugs\/ScienceResearch\/%20ResearchAreas\/ucm076777.pdf."},{"issue":"2","key":"698_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","volume":"63","author":"M Chen","year":"2015","unstructured":"Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63(2):503\u201314.","journal-title":"J Hepatol"},{"issue":"2","key":"698_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0034-1375953","volume":"34","author":"ES Bj\u00f6rnsson","year":"2014","unstructured":"Bj\u00f6rnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115\u201322.","journal-title":"Semin Liver Dis"},{"key":"698_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fphar.2016.00267","volume":"7","author":"M Robles-D\u00edaz","year":"2016","unstructured":"Robles-D\u00edaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkers in DILI: one more step forward. Front Pharmacol. 2016;7:267.","journal-title":"Front Pharmacol."},{"issue":"7","key":"698_CR38","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1021\/tx1000865","volume":"23","author":"N Greene","year":"2010","unstructured":"Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23(7):1215\u201322.","journal-title":"Chem Res Toxicol"},{"issue":"15\u201316","key":"698_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","volume":"16","author":"M Chen","year":"2011","unstructured":"Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today. 2011;16(15\u201316):697\u2013703.","journal-title":"Drug Discov Today."},{"key":"698_CR40","unstructured":"Drug-induced livery injury: premarketing clinical evaluation. Guidance for industry. US Food and Drug Administration, 2009. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatory."},{"issue":"1","key":"698_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.gastro.2014.05.027","volume":"147","author":"A Regev","year":"2014","unstructured":"Regev A, Bj\u00f6rnsson ES. Drug-induced liver injury: morbidity, mortality, and Hy\u2019s law. Gastroenterology. 2014;147(1):20\u20134.","journal-title":"Gastroenterology"},{"issue":"5","key":"698_CR42","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.1840090504","volume":"9","author":"JH Lewis","year":"1989","unstructured":"Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679\u201385.","journal-title":"Hepatology"},{"key":"698_CR43","first-page":"639","volume-title":"Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver","author":"HJ Zimmerman","year":"1999","unstructured":"Zimmerman HJ. Drugs used in cardiovascular disease. In: Zimmerman HJ, editor. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 639\u201371.","edition":"2"},{"issue":"9","key":"698_CR44","doi-asserted-by":"publisher","first-page":"1082.e1-4","DOI":"10.1016\/j.ajem.2007.02.045","volume":"25","author":"E Rizzioli","year":"2007","unstructured":"Rizzioli E, Incasa E, Gamberini S, Savelli S, Zangirolami A, Tampieri M. Acute toxic hepatitis after amiodarone intravenous loading. Am J Emerg Med. 2007;25(9):1082.e1-4.","journal-title":"Am J Emerg Med"},{"issue":"7","key":"698_CR45","doi-asserted-by":"publisher","first-page":"843.e5-6","DOI":"10.1016\/j.ajem.2010.03.035","volume":"29","author":"A Verhovez","year":"2011","unstructured":"Verhovez A, Elia F, Riva A, Ferrari G, Apr\u00e0 F. Acute liver injury after intravenous amiodarone: a case report. Am J Emerg Med. 2011;29(7):843.e5-6.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"698_CR46","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/hep.1840080326","volume":"8","author":"M Pirovino","year":"1988","unstructured":"Pirovino M, M\u00fcller O, Zysset T, Honegger U. Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology. 1988;8(3):591\u20138.","journal-title":"Hepatology"},{"key":"698_CR47","first-page":"431","volume-title":"Drug-induced liver disease","author":"GC Farrell","year":"1994","unstructured":"Farrell GC. Drug-induced steatohepatitis. In: Farrell GD, editor. Drug-induced liver disease. Edinburge: Churchill Livingstone; 1994. p. 431\u20138."},{"issue":"2","key":"698_CR48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"698_CR49","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","volume":"28","author":"F Thiessard","year":"2005","unstructured":"Thiessard F, Roux E, Miremont-Salam\u00e9 G, Fourrier-R\u00e9glat A, Haramburu F, Tubert-Bitter P, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986\u20132001). Drug Saf. 2005;28(8):731\u201340.","journal-title":"Drug Saf"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-0698-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:46:16Z","timestamp":1613609176000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-0698-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-0698-5","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]},"assertion":[{"value":"9 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}